linjc16/ctgov huggingface dataset:
Anterior Mediastinum Teratoma: A Case Report

Study Overview
=================
Brief Summary
-----------------
The investigators report a case of a 39-year-old man who presented an anterior mediastinal cystic mature teratoma. Those kind of tumor contain elements derived from more than one of the three primary germ layers (ectoderm, mesoderm, endoderm), frequently arranged in a haphazard manner. They arise from totipotent cells and, therefore, are primarily found in gonads, and more rarely in primitive cells kidnapped in other parts of the body. The tissues are immature to well differentiated and foreign to the anatomic site. Mature teratomas are either cystic or solid, although the cystic presentation predominates in gonadal sites. Benign teratomas are the most common mediastinal germ cell tumor, accounting 70% of the mediastinal germ cell tumors in children and 60% of those in adults. Immature teratomas are potentially malignant tumors; their prognosis is influenced by the anatomic site of the tumor, patient age, and the fraction of the tumor that is immature. Treatment of benign mediastinal teratoma includes complete surgical resection, with results in a excellent long-term cure rates. Complete resection of teratomas should be the goal of treatment.

Official Title
-----------------
Case Report of a 39 Years Old Man That Has Been Cured by a Total Resection of a Anterior Mediastinum Teratoma.

Conditions
-----------------
Teratoma

Intervention / Treatment
-----------------
* Procedure: right thoracotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of mediastinum teratoma Exclusion Criteria: Tumor absent

Ages Eligible for Study
-----------------
Minimum Age: 39 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| tumor<br> | Procedure: right thoracotomy<br>* complete surgical resection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cure |  | one month after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Teratoma, Mediastinum
Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice

Study Overview
=================
Brief Summary
-----------------
MARILIA is a prospective, non-interventional, multicenter study. The purpose of this study is to describe the acceptability of Amenorrhea in contraception indication of Mirena users during one year follow up in medical practice. 500 patients in 20 centers will be enrolled in the study. Bleeding profile, removal or non-removal of the IUS (IntraUterine System) will be evaluated.

Official Title
-----------------
Mirena and Amenorrhea Related acceptabILity in Contraception indIcAtion

Conditions
-----------------
Female Contraception

Intervention / Treatment
-----------------
* Drug: Levonorgestrel IUD (Mirena, BAY86-5028)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 19-40 years at the time of Mirena IUD insertion Using Mirena only for contraception indication Never having used the product before No heavy menstrual bleeding diagnosed Have signed informed consent to participate in this study Exclusion Criteria: Nulliparous Pregnancy Mirena's contre-indication Mirena for HMB Abnormal bleeding pattern

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Levonorgestrel IUD (Mirena, BAY86-5028)<br>* Women who have been prescribed Mirena in contraception; followed up for 12 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Mirena users who have at least one period of Amenorrhea of at least three months |  | 12 months | 
| Cumulative incidence rate of Amenorrhea over the duration of follow up period in Mirena users |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Mirena users who have menstrual disorders |  | 12 months | 
| Proportion of Mirena users with menorrhagia |  | 12 months | 
| Cumulative rate of satisfaction in Mirena users |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mirena, Contraception, Amenorrhea
Early Results of Slanted Recession of the Lateral Rectus Muscle for Intermittent Exotropia With Convergence Weakness

Study Overview
=================
Brief Summary
-----------------
This study was conducted to evaluate results of slanted recession of the lateral rectus muscle for intermittent exotropia with convergence weakness

Detailed Description
-----------------
This prospective study included 31 patients who underwent slanted lateral rectus muscle recession for intermittent exotropia with convergence weakness. Measurements of preoperative and postoperative deviation angle, stereopsis was performed.

Official Title
-----------------
Early Results of Slanted Recession of the Lateral Rectus Muscle for Intermittent Exotropia With Convergence Weakness; A Prospective Study

Conditions
-----------------
Intermittent Exotropia

Intervention / Treatment
-----------------
* Procedure: Slanted recession of the lateral rectus muscle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with intermittent exotropia greater at near than at distance by 10 prism diopters or more Patients with follow up duration greater than 6 months Exclusion Criteria: Patients with previous ocular or strabismus surgery Patients with ocular or neurologic pathologic conditions Follow up duration less than 6 months

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lateral Rectus Muscle Slanted Recession<br>Slanted recession of the lateral rectus muscle for the intermittent exotropia with convergence weakness | Procedure: Slanted recession of the lateral rectus muscle<br>* All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline of exodeviations angle after slanted recession surgery at 6 months. | Measurement of deviation angle after slanted recession surgery was performed. | preop, 6months postop | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline of near-distance difference after slanted recession surgery at 6 months | Measurement of stereopsis after slanted recession was performed. | preop, 6 months postop |
Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function

Study Overview
=================
Brief Summary
-----------------
Explore the effects of anti-VEGF targeted drugs on blood pressure and endothelial function in cancer patients.

Detailed Description
-----------------
Thirty tumor patients with anti-VEGF drugs were selected. Demographic information and clinical information of all patients were collected before chemotherapy. Ambulatory blood pressure monitoring and endothelial function measurement (PWV, EndoPAT) were performed. Ambulatory blood pressure and PWV were reviewed at 2 weeks and 1 month. And EndoPAT, to evaluate the effects of anti-VEGF drugs on blood pressure and endothelial function in cancer patients.

Official Title
-----------------
Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function

Conditions
-----------------
Cardiac Toxicity, VEGF, Endothelial Dysfunction

Intervention / Treatment
-----------------
* Drug: Anti-VEGF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tumor patients using anti-VEGF drugs Exclusion Criteria: Hypertension, coronary heart disease, valvular heart disease, cardiomyopathy and other organic heart diseases, exclude liver and kidney failure, severe cerebrovascular disease, chronic obstructive pulmonary disease, rheumatic immune system disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tumor patients using anti-VEGF drugs<br> | Drug: Anti-VEGF<br>* Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time ending | 30 days after using the Anti-VEGF Targeted Drugs | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac safety, anti-VEGF drugs, Endothelial dysfunction
Observational Program Neo-Penotran® Forte

Study Overview
=================
Brief Summary
-----------------
Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or mixed infection. Neo-Penotran Forte is registered for treatment of these most common vaginal infections. Efficacy and safety of this product is already established, and this observational study was designed to learn more about practical use of Neo-Penotran® Forte in real life setting.

Official Title
-----------------
Observational Program Neo-Penotran® Forte

Conditions
-----------------
Vaginal Candidiasis, Bacterial Vaginosis, Trichomonal Vaginitis

Intervention / Treatment
-----------------
* Drug: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed. Exclusion Criteria: Presence of contraindications according to package insert.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)<br>* Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent rate of different vaginal infections |  | Approximately within 6 months after the last patient last visit. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical characteristics of vaginitis after treatment. |  | Depending on treatment time chosen by the physician, after 7 or 14 days. | 
| Change of microbiological characteristics after treatment |  | Depending on treatment time chosen by the physician, after 7 or 14 days. | 
| Patient rating of tolerability and treatment results |  | Depending on treatment time chosen by the physician, after 7 or 14 days. | 
| Physician's rating of tolerability and treatment results |  | Depending on treatment time chosen by the physician, after 7 or 14 days. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vaginal candidiasis, Bacterial vaginosis (also known as non-specific, or Gardnerellosis, or anaerobic vaginosis), Trichomonal vaginitis, Vaginitis due to mixed infection
Prevalence and Prognosis of Cardiac Amiloidosis in Turkey

Study Overview
=================
Brief Summary
-----------------
Patients with left ventricular hypertrophy are further examined according to an algorithm to check if they have a cardiac amyloidosis

Official Title
-----------------
Prevalence and Prognosis of Cardiac Amiloidosis in Turkey- Registry Study

Conditions
-----------------
Cardiac Amyloidosis

Intervention / Treatment
-----------------
* Behavioral: Algorithm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with left ventricular hypertrophy without left ventricular pressure or volume (IVS≥13mm) Patients with left ventricular hypertrophy and hypertension or aortic stenosis without left ventricular pressure or volume (IVS>15mm) Exclusion Criteria: Patients with left ventricular pressure or volume except the ones with aortic stenosis and arterial hypertension Patients with sigmoid septum and their hypertrophy limited in sigmoid area Patients with highly probable sarcometric hypertrophy cardiomyopathy confirmed with LV morhpology and genetic testing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Algorithm|Algorithm|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac Amyloidosis | Patients with left ventricular hypertrophy and Cardiac Amyloidosis | Upon screening |
Comparison of Post-operative Symptoms After Two Surgeries for Patients With Pelvic Organ Prolapse

Study Overview
=================
Brief Summary
-----------------
Collect and review the patients who underwent surgical treatment due to pelvic floor organ prolapse from 2020 to 2021, make statistics on their postoperative questionnaire data, and evaluate the clinical effects of different surgical methods

Official Title
-----------------
Comparison of Post-operative Lower Urinary Tract Symptoms After Sacrospinous Ligament Fixation or Extraperitoneal High Uterosacral Ligament Suspension for Patients With Pelvic Organ Prolapse

Conditions
-----------------
Pelvic Organ Prolapse

Intervention / Treatment
-----------------
* Procedure: Two different surgical methods


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 30 years; Because pelvic organ prolapse in our hospital, we performed extraperitoneal high sacral ligament suspension or sacrospinal ligament fixation; ③ Those who have no surgical contraindication and can tolerate surgery and anesthesia. Exclusion Criteria: Those who cannot tolerate surgery and anesthesia; ② Patients receiving other tip suspension techniques.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients had pelvic organ prolapse who undergone Sacrospinal ligament fixation<br> | Procedure: Two different surgical methods<br>* SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension<br>|
| patients had pelvic organ prolapse who undergone Extraperitoneal high sacral ligament suspension<br> | Procedure: Two different surgical methods<br>* SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in POP-Q score at different time nodes | Gynecological examination | pre-operation and post-operation(1month, 3 months and 6 months ) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| UDI-6 scores at different time nodes | Questionnaires on lower urinary tract symptoms and quality of life | pre-operation and post-operation(1month, 3 months and 6 months ) | 
| PFDI-20 scores at different time nodes | Questionnaires on lower urinary tract symptoms and quality of life | pre-operation and post-operation(1month, 3 months and 6 months ) | 
| OABss scores at different time nodes | Questionnaires on lower urinary tract symptoms | pre-operation and post-operation(1month, 3 months and 6 months ) |
Comparison of Dydrogesterone and Micronized Progesterone Treatments in the Treatment of Threatened Miscarriage.

Study Overview
=================
Brief Summary
-----------------
In this study, we aimed to compare the effects of two drugs used for the threated miscarriage on the miscarriage rate.

Detailed Description
-----------------
About 140 pregnant women who applied to our clinic due to the threated miscarriage in the first trimester will be randomly given micronized progesterone to half and dydrogesterone to the other half. After the treatment, the miscarriage rates in the groups will be compared.

Official Title
-----------------
Comparison of Dydrogesterone and Micronized Progesterone Treatments in the Treatment of Threatened Miscarriage.

Conditions
-----------------
Miscarriage Threatening

Intervention / Treatment
-----------------
* Drug: Duphastone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women with threated miscarriage in the first trimester. Exclusion Criteria: - pregnant women with abortus incipiens.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Micronised progesterone<br>Micronized progesterone will be given to 70 pregnant women with threated miscarriage. | Drug: Duphastone<br>* dydrogesterone hormone<br>|
| Experimental: Dydrogesterone<br>Dydrogesterone will be given to 70 pregnant women with threated miscarriage. | Drug: Duphastone<br>* dydrogesterone hormone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Miscarriage rate | Effects of two drugs to be used on live birth rate in pregnant women with threated miscarriage | One year |
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension

Conditions
-----------------
Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: brimonidine/timolol fixed combination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes Patient requires IOP-lowering drug in both eyes Exclusion Criteria: Uncontrolled medical conditions contraindication to beta-adrenoceptor antagonist or brimonidine therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: brimonidine/timolol fixed combination|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP |  |  |
The VEPRO Trial: A Cross-Over Randomised Controlled Trial Comparing 2 Corrective Lenses for Patients With Presbyopia

Study Overview
=================
Brief Summary
-----------------
The VEPRO trial is a cross-over randomised controlled trial comparing 2 corrective lenses for patients with presbyopia. The aim of the study is to compare the effectiveness of two corrective lenses: an old generation (Varilux Comfort Orma Crizal) and a new generation (Varilux Panamic Orma Crizal) of corrective lenses prescribed in presbyopia.

Official Title
-----------------
The VEPRO Trial: A Cross-Over Randomised Controlled Trial Comparing 2 Corrective Lenses for Patients With Presbyopia

Conditions
-----------------
Presbyopia

Intervention / Treatment
-----------------
* Device: a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)
* Device: an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 43 to 60 years old outpatients wearing corrective lenses for presbyopia, referred to an optician within the last 6 months for a change in their optical correction associated hyperopia or astigmatism, the required correction had to be ≤ 3 dioptres in that case understanding, speaking French and able to answer a questionnaire Exclusion Criteria: first prescription of corrective lenses for presbyopia associated strabism associated amblyopia orthoptics therapy associated anisometropia > 1.5 dioptres patients treated for diabetes

Ages Eligible for Study
-----------------
Minimum Age: 43 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Device: a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)<br> <br> * Other names: Essilor (R);|
| Active Comparator: 2<br> | Device: an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)<br> <br> * Other names: Essilor (R);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient preference for a corrective lens |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| subjective measures of different areas of visual performance. |  | 8 weeks |